drugset / Trial / NCT01330017

Effects of Phenylephrine on Nasal Congestion in Participants With Seasonal Allergic Rhinitis (P08156 AM2)(Completed)

NCT01330017

Phase 2 Completed 539 enrolled Bayer
RandomizedParallel-groupOpen-labelTreatment

Summary

The trial will evaluate the nasal congestion symptom relief of the approved 10 mg phenylephrine (PE) dose and the higher 20 mg, 30 mg, and 40 mg PE doses compared with placebo in participants with histories of seasonal allergic rhinitis, using loratadine as background medication.

Timeline

Start
2011-03
Primary completion
2011-05
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Phenylephrine Small molecule 10 mg Oral
Subject Phenylephrine Small molecule 20 mg Oral
Subject Phenylephrine Small molecule 30 mg Oral
Subject Phenylephrine Small molecule 40 mg Oral
Background Loratadine Small molecule 10 mg Oral